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Abstract: Background and Objectives: People living with HIV/AIDS are at an increased risk of 
developing cancer. The goals of this study were to obtain data on the prevalence of HIV in the can-
cer population and vice versa at a major tertiary cancer and HIV center in North India. 
Methods: This cross-sectional study was conducted over a 3-year period from July 2013 to June 
2016, wherein successive HIV positive patients from an anti-retroviral therapy (ART) center were 
screened for malignancy. Simultaneously, successive cancer patients at the cancer center were 
screened for HIV. Baseline demographic details, risk factors, and laboratory investigations were ob-
tained for all the patients. 
Results: Among the 999 HIV-positive patients at the ART center, the prevalence of malignancy was 
2% (n=20; 95% confidence interval (CI) 1.13, 2.87). Among the 998 patients with a malignancy, the 
prevalence of HIV infection was 0.9% (n=9; 95% CI 0.31, 1.49). Weight loss, loss of appetite, and 
fever were the most common symptoms in patients with HIV and cancer. Among 29 patients with 
HIV and cancer, AIDS-defining cancer was found in 19 patients; non-Hodgkin’s lymphoma was the 
most common malignancy reported (n=13). 
Interpretation and Conclusion: There is a low prevalence of HIV in cancer patients as well as a 
low prevalence of cancer in HIV patients. AIDS-defining cancers remain much more common than 
non-AIDS-defining cancers. With the increased coverage of ART, it is expected that non-AIDS-
defining cancers will increase, as is evident from data from more developed countries.  
Keywords: AIDS-defining cancer, cancer, HIV, invasive cervical cancer, non-Hodgkin’s lymphoma, ART. 
1. BACKGROUND 
Human immunodeficiency virus (HIV) infection is a risk 
factor for cancer [1, 2]. HIV-associated cancers can be di-
vided into acquired immune deficiency syndrome (AIDS)-
defining cancers (ADC) and non-AIDS-defining cancers 
(NADC) [2]. The availability of effective antiretroviral ther-
apy (ART) has lowered the incidence of cancer but there has 
been a simultaneous increase in the life expectancy of people 
living with HIV [3]. Consequently, the overall incidence of  
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cancer and AIDS-defining cancer has stabilized over the last 
two decades (except invasive cervical cancer), while there 
has been an absolute increase in NADC [2-6]. HIV-
associated cancer is one of the leading causes of death in 
HIV patients [7-9]. 
ADC include non-Hodgkin’s lymphoma (NHL), invasive 
cervical carcinoma, and Kaposi’s sarcoma (KS) [10]. NADC 
include lung cancer, anal cancer, Hodgkin’s lymphoma, etc. 
The standardized incidence ratio (which compares the cancer 
rate in patients with HIV to the expected rate in the general 
population) [11] varies from 2 in lung cancer to 498 in Ka-
posi’s sarcoma. NHL remains the most common cancer in 
patients with HIV worldwide [2, 12]. 
1873-4251/18 $58.00+.00 © 2018 Bentham Science Publishers  
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Risk factors for cancer in HIV include immunosuppres-
sion, oncogenic potential of HIV [13], co-infection with 
other oncogenic virus such as hepatitis B and C [13], hu-
man herpes virus-8 (HHV-8) infection [14, 15], human 
papilloma virus (HPV) [16], Epstein-Barr virus (EBV) [17, 
18], etc. HIV can also sensitize the cells to the oncogenic 
potential of tobacco, as suggested by an increase in the risk 
of lung cancer in people living with HIV (three times the 
general population) after adjustment for smoking status 
[13].  
In 2016, there were 36.7 million people living with HIV 
worldwide; 2.1 million of these lived in India [19, 20]. Based 
on regional records, NHL is the most common cancer overall 
[21-24] and Kaposi’s sarcoma is rare [23]. Increasing access 
to ART [25] is expected to decrease the overall incidence of 
cancer in this population, but the spectrum of cancer in peo-
ple living with HIV in India needs to be better understood for 
effective screening. 
We aim to look at the prevalence and spectrum of cancer 
in HIV patients at a tertiary care referral center in North In-
dia. 
2. METHODS 
From July 2013 to June 2016, we used a structured his-
tory and physical examination to screen successive adult 
(≥18 years) HIV-positive patients, irrespective of whether or 
not on any anti-retroviral therapy (ART), who presented at 
the ART center at the hospital for malignancy. The insti-
tute’s ethics committee approved the protocol. Written in-
formed consent was obtained from all the participants prior 
to their participation in the study.  
Baseline demographic data were recorded regarding edu-
cation, occupation, marital status, status of spouse and chil-
dren, and likely mode of transmission. CD4 count was as-
sessed for all the patients with HIV and cancer at the ART 
center. CD4 cell counts were measured by flow cytometry 
using BD FACS CALIBUR and fluorescein monoclonal 
antibodies (Becton Dickenson Biosciences, San Jose, CA, 
USA).  
We assessed for known risk factors for malignancies 
such as current or former smoking, tobacco chewing, and 
alcohol intake. Those suspicious for malignancy were further 
evaluated with radiological investigations such as X-ray, 
ultrasound, computed tomography (CT) scan, magnetic reso-
nance imaging (MRI), and positron-emission tomography 
(PET)-CT scan of the region of interest. All the malignancies 
were confirmed by histopathological examination. The time 
since the diagnosis of HIV and malignancy was recorded for 
all the patients. The overall prevalence of malignancy in HIV 
was calculated. 
All the consecutive patients who presented at the cancer 
center with a confirmed diagnosis of a malignancy were 
screened for HIV antibodies using ELISA. All patients, irre-
spective of type and stage of malignancy were included in 
the study after due consent. Biopsy reports of all the patients 
diagnosed elsewhere were reviewed at this hospital for con-
firmation of diagnosis. The patients who tested positive for 
HIV were referred to the ART clinic at the All India Insti-
tutes of Medical Sciences (AIIMS) for HIV treatment and 
follow-up. 
The study was continued till 1000 patients each were re-
cruited at the ART center and the cancer center respectively. 
All the patients with HIV and cancer were followed-up 
for treatment response and outcome for one year post-
enrollment. 
The data were recorded in a predesigned Excel spread-
sheet. All the participants were given a unique code number. 
We calculated the prevalence of cancer in the HIV patients 
and the prevalence of HIV infection in patients with cancer 
over the three-year period. The descriptive statistics were 
calculated, including means and standard deviations for the 
continuous variables and percentages for the categorical 
variables. One-way ANOVA with Bonferroni’s correction 
was used to find significant differences in the data following 
parametric distribution, while the Wilcoxon rank-sum test 
was used to find differences in CD4 counts between the 
groups. 
3. RESULTS 
There were 999 HIV-positive patients enrolled from the 
ART clinic and 998 patients from the cancer clinic. Most of 
the patients at the ART center were males, whereas most 
patients at the cancer center were females.  
Of the 999 HIV-positive patients, 20 patients were diag-
nosed with a malignancy. 
The overall prevalence of cancer in the HIV patients was 
2% (20/999) [95% confidence interval (CI)I 1.13, 2.87]. 
Of the 998 cancer patients, 9 patients had HIV infection. 
The overall prevalence of HIV in the cancer patients was 
0.9% (9/998) (95% CI 0.31, 1.49). For the analysis, we di-
vided the patient population into three groups: HIV only 
(group 1, n=979), cancer only (group 2, n=989), and HIV 
and cancer (group 3, n=29) (Table 1). 
Most of the patients in the three groups did not smoke or 
consume significant amounts of alcohol. The patients with 
HIV and cancer were older than those with HIV only 
(44.8±10.5 vs 36.7±9.2 years, p-value <0.05). 
Almost half of the patients with HIV and cancer had fe-
ver, involuntary weight loss, and loss of appetite in the pre-
ceding six months, while only one-third of the patients in the 
HIV only group had these symptoms. There was no signifi-
cant difference in the CD4 counts in groups 1 and 3 at the 
time of diagnosis of cancer (median CD4 count 246 vs 188, 
p-value >0.05).  
Among the patients with HIV and cancer (n=29), 22 were 
male and 7 were female. Overall, 19 patients had AIDS-
defining cancers while 10 had non-AIDS-defining cancers. 
The most common malignancy was non-Hodgkin’s lym-
phoma (13/29) followed by invasive cervical carcinoma 
(6/29). No case of KS was observed.  
There was only one case of hepatitis B co-infection in pa-
tients with HIV and cancer. At one-year follow up, 19 pa-
tients were alive, 8 patients had died, and 2 patients could 
not be traced.  
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Table 1.  Demographic variables, risk factors and malignancy distribution. 
Variables 
HIV Only 
n=979 
Cancer Only  
n=989 
HIV and Cancer  
n=29 
Age (years) 36.7±9.2 48.5±13.7 44.8±10.5 
Male (%) 740 (75.5%) 361 (36.5%) 22 (75.8%) 
CD4 (cells/mm3) 246 (155,377)  188 (101,411) 
Marital status    
• Married 361 (37%) 909 (92%) 25 (93%) 
• Unmarried 618 (63%) 80 (8%) 4 (7%) 
Transmission route    
• Heterosexual 902 (92%) - 21 (72.4%) 
• Mother to child transmission 15 (1.5%)  - 
• Other 62 (6.3%)  8 (27.6%) 
Smoking    
• Current smoker 47 (5%) 6 (0.6%) 3 (10.3%) 
• Past smoker 187 (19%) 43 (4.3%) 8 (27.5%) 
• Never smoked 745 (76%) 942 (95%) 18 (62%) 
Alcohol consumption    
• Habitual drinker 723 (73.8%) 976 (98.6%) 20 (69%) 
• Non-Alcoholic 256 (26.2%) 13 (1.4%) 9 (31%) 
Substance abuse    
• Current or past  8 (0.8%) 2 (0.2%) 3 (10.4%) 
• Never 971 (99.2) 987 (99.8%) 26 (89.6%) 
Fever 340 (34.7%) 65 (6.6%) 15 (51.2%) 
Weight Loss 386 (39.3%) 272 (27.5% 15 (51.2%) 
Loss of appetite 333 (34%) 269 (27.2%) 15 (51.2% 
Lymphadenopathy 152 (15.5%) 237 (24%) 8 (27.6%) 
Malignancy type    
• Non-Hodgkin’s lymphoma  121 (12.4%) 13 (44.8%) 
• Carcinoma Cervix  147 (15%) 6 (20.7%) 
• Hodgkin’s lymphoma  37 (3.4%) 4 (13.8%) 
• Carcinoma Lung  41 (4.2%) 1 (3.4%) 
• Carcinoma Gall bladder  24 (2.4%) 1 (3.4%) 
• Sino-nasal SCC  15 (1.5%) 1 (3.4%) 
• Skin SCC  2 (0.2%) 1 (3.4%) 
• Adenocarcinoma Colon  31 (3.1%) 2 (6.8%) 
Data is presented as mean ± standard deviation, Mean (Inter-quartile range); SCC: Squamous cell carcinoma 
 
4. DISCUSSION 
Our study suggests that approximately 2% of HIV pa-
tients had cancer, while 1% of cancer patients had HIV in-
fection. AIDS-defining cancers remain more common than 
non-AIDS-defining cancers. In more developed countries 
with a higher life expectancy, non-AIDS-defining cancers 
predominate. It is expected that better coverage of ART, 
control of communicable diseases, and increased longevity 
would lead to an increase in non-AIDS-defining cancers and 
a decrease in AIDS-defining cancers [2, 26, 27].  
The prevalence of HIV infection in cancer patients is 
very low, but it is approximately four times the national 
population (the national prevalence of HIV infection in India 
is 0.26%) [28]. In a similar report from Maharashtra, India, 
3,832 patients were studied and the prevalence of HIV infec-
tion was only 1.2% [29]. 
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AIDS-defining cancer such as NHL was around four 
times more common in patients with HIV compared to HIV-
negative cancer patients. At the same center as the present 
study (AIIMS), a retrospective study analyzing malignancy 
in HIV patients during the initial years of ART (2005-2013) 
suggested a similar infrequent occurrence of malignancy in 
HIV, with NHL being the most common [30]. Most regional 
studies from India concur that NHL is the most common 
malignancy in HIV and KS is very rare [21-23, 29-33]. One 
of the reasons postulated is the low seroprevalence of HHV-
8 in the Indian population [34]. However, a recent study by 
Munawwar et al. reported that 26% of 165 HIV-positive 
ART-naïve Indian men (90% heterosexual) had antibodies 
against HHV-8 [35]. The role of factors additional to HHV-8 
in the pathogenesis of KS needs to be explored. 
Diffuse large B-cell lymphoma is the most common sub-
type of NHL overall as well in the HIV population [2, 23, 
24]. While EBV is commonly associated with immunodefi-
ciency-related Hodgkin’s lymphoma, its role in the patho-
genesis of NHL in HIV varies, with most cases of primary 
CNS lymphoma expressing EBV proteins while rarely being 
associated with Burkitt lymphoma [36-38]. Outcomes of 
lymphoma have been worse in HIV-positive patients [39-
41]. With effective chemotherapy and ART, there has been a 
better outcome reported with some studies showing similar 
outcomes as in HIV-negative patients [39, 42-44]. 
Patients with HIV are susceptible to chronic infection by 
oncogenic strains of HPV. In addition to causing cervical 
cancer, HPV also causes anal cancers and head and neck 
cancers [2, 45]. There is a high prevalence of HPV infection 
in HIV-infected women; almost one in four such patients 
have HPV co-infection with a high rate of intraepithelial 
neoplasia [46].  
In this study, we observed a low prevalence of malignan-
cies at the time of HIV diagnosis. We screened many succes-
sive patients at the ART and cancer center. It is yet to be 
observed whether HIV positive patients with malignancies 
have similar outcome as seronegative patients of the same 
stage. Drug interactions among chemotherapeutic agents and 
ART are also largely unknown. Though we followed HIV-
cancer patients for one-year post-enrollment, stage of the 
diagnosed malignancy, treatment given and response is un-
known. With effective ART and improvement in immunity it 
is expected that incidence of malignancy will be reduced, 
follow-up studies will help understand natural history of this 
disease. 
HIV-related cancers are preventable through vaccination 
and early and highly active ART [2, 47, 48]. Screening of all 
HIV patients with clinical and radiological examinations 
should be conducted for early diagnosis and treatment of 
cancer. With this study, we have created a national HIV-
cancer registry that will help to understand the spectrum of 
HIV-related malignancy in the hospital and community-
based setting. 
CONCLUSION 
There is a low prevalence of cancer at the time of HIV 
diagnosis in North India. Similarly, HIV infection is rare in 
cancer patients. AIDS defining cancers remain most preva-
lent, while Kaposi’s sarcoma is rare. Follow-up of these pa-
tients is required to see whether these patients have similar 
outcomes as compared to seronegative patients of the same 
stage. 
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